446 lines
26 KiB
HTML
446 lines
26 KiB
HTML
<!DOCTYPE html>
|
||
<html lang="zh-CN" data-theme="night">
|
||
<head>
|
||
<meta charset="UTF-8">
|
||
<meta name="viewport" content="width=device-width, initial-scale=1.0">
|
||
<title>深度投研报告: 减肥药-众生药业RAY1225双靶点</title>
|
||
<script src="https://cdn.tailwindcss.com"></script>
|
||
<link href="https://cdn.jsdelivr.net/npm/daisyui@4.10.2/dist/full.min.css" rel="stylesheet" type="text/css" />
|
||
<script defer src="https://cdn.jsdelivr.net/npm/alpinejs@3.x.x/dist/cdn.min.js"></script>
|
||
<script src="https://cdn.jsdelivr.net/npm/echarts@5.5.0/dist/echarts.min.js"></script>
|
||
<style>
|
||
@import url('https://fonts.googleapis.com/css2?family=Poppins:wght@300;400;500;600;700&display=swap');
|
||
|
||
body {
|
||
font-family: 'Poppins', sans-serif;
|
||
background-color: #0a0920;
|
||
background-image:
|
||
radial-gradient(circle at 10% 10%, rgba(128, 0, 128, 0.2) 0%, transparent 40%),
|
||
radial-gradient(circle at 80% 90%, rgba(0, 128, 255, 0.2) 0%, transparent 40%),
|
||
radial-gradient(circle at 50% 50%, rgba(255, 255, 255, 0.05) 0%, transparent 30%);
|
||
background-attachment: fixed;
|
||
}
|
||
|
||
.glass-card {
|
||
background: rgba(23, 23, 43, 0.5);
|
||
backdrop-filter: blur(16px) saturate(180%);
|
||
-webkit-backdrop-filter: blur(16px) saturate(180%);
|
||
border: 1px solid rgba(255, 255, 255, 0.125);
|
||
transition: all 0.3s ease;
|
||
}
|
||
|
||
.glass-card:hover {
|
||
transform: translateY(-5px);
|
||
box-shadow: 0 0 30px rgba(0, 191, 255, 0.3);
|
||
}
|
||
|
||
.glow-text {
|
||
text-shadow: 0 0 8px rgba(0, 191, 255, 0.6);
|
||
}
|
||
|
||
.glow-border {
|
||
position: relative;
|
||
}
|
||
|
||
.glow-border::before {
|
||
content: '';
|
||
position: absolute;
|
||
top: 0;
|
||
left: 0;
|
||
right: 0;
|
||
bottom: 0;
|
||
border-radius: inherit;
|
||
border: 1px solid transparent;
|
||
background: linear-gradient(120deg, rgba(0, 191, 255, 0.5), rgba(138, 43, 226, 0.5)) border-box;
|
||
-webkit-mask:
|
||
linear-gradient(#fff 0 0) padding-box,
|
||
linear-gradient(#fff 0 0);
|
||
-webkit-mask-composite: destination-out;
|
||
mask-composite: exclude;
|
||
pointer-events: none;
|
||
}
|
||
|
||
.bento-grid {
|
||
display: grid;
|
||
gap: 1rem;
|
||
grid-template-columns: repeat(auto-fit, minmax(300px, 1fr));
|
||
}
|
||
|
||
.table thead th {
|
||
background-color: rgba(0, 191, 255, 0.1);
|
||
color: #E5E7EB;
|
||
}
|
||
|
||
.table tbody tr {
|
||
border-color: rgba(255, 255, 255, 0.1);
|
||
}
|
||
|
||
.table tbody tr:hover {
|
||
background-color: rgba(0, 191, 255, 0.05);
|
||
}
|
||
|
||
[x-cloak] { display: none !important; }
|
||
|
||
</style>
|
||
</head>
|
||
<body class="text-gray-200">
|
||
<div class="fixed top-0 left-0 w-full p-2 text-center text-xs text-gray-500 bg-black/30 z-50">
|
||
北京价值前沿科技有限公司 AI投研agent：“价小前投研” 进行投研呈现
|
||
</div>
|
||
|
||
<div class="container mx-auto px-4 py-16">
|
||
|
||
<!-- Header -->
|
||
<header class="text-center mb-16">
|
||
<h1 class="text-4xl md:text-6xl font-bold glow-text bg-clip-text text-transparent bg-gradient-to-r from-cyan-400 to-purple-500 mb-4">
|
||
众生药业 RAY1225 双靶点
|
||
</h1>
|
||
<p class="text-xl text-gray-400">深度投研报告：一款潜力Best-in-Class减肥新药的价值解析</p>
|
||
</header>
|
||
|
||
<main class="space-y-12">
|
||
|
||
<!-- Insight: Core Logic -->
|
||
<section class="glass-card rounded-3xl p-8 glow-border">
|
||
<h2 class="text-2xl font-bold text-cyan-400 mb-4">核心观点摘要</h2>
|
||
<p class="text-gray-300 leading-relaxed">
|
||
众生药业的RAY1225是一款处于后期临床阶段、数据驱动的潜力“Best-in-Class”减肥药。其核心驱动力源于<strong class="text-white">“疗效+安全+便捷”</strong>三位一体的差异化优势，即在对标甚至超越行业标杆（替尔泊肽）减重疗效的同时，展现出更优的安全性（胃肠道反应更低）和更便捷的双周给药方案。当前概念正从临床价值验证转向商业价值（尤其是海外授权BD）兑现的关键节点，未来潜力巨大，但同时也面临着激烈的市场竞争和临床/商业化不确定性。
|
||
</p>
|
||
</section>
|
||
|
||
<!-- Bento Grid: Key Advantages -->
|
||
<section>
|
||
<h2 class="text-3xl font-bold text-center mb-8 glow-text">RAY1225 核心竞争优势</h2>
|
||
<div class="grid grid-cols-1 md:grid-cols-3 gap-6">
|
||
<div class="glass-card rounded-3xl p-6 col-span-1 md:col-span-2 glow-border">
|
||
<h3 class="text-xl font-semibold text-purple-400 mb-2">疗效对标最优 (Best-in-Class Efficacy)</h3>
|
||
<p class="text-3xl font-bold text-white mb-2">-15.05%</p>
|
||
<p class="text-gray-400">9mg剂量组治疗24周平均体重降幅，数值上可比肩甚至优于礼来替尔泊肽更高剂量在同时间点的减重效果。88%的受试者减重超10%，应答率优异。</p>
|
||
</div>
|
||
<div class="glass-card rounded-3xl p-6 glow-border">
|
||
<h3 class="text-xl font-semibold text-cyan-400 mb-2">便捷性提升 (Enhanced Convenience)</h3>
|
||
<p class="text-3xl font-bold text-white mb-2">Q2W</p>
|
||
<p class="text-gray-400">“两周一次”给药，半衰期(9-11天)为竞品替尔泊肽(4-5天)的两倍。给药频率减半，极大提升患者依从性。</p>
|
||
</div>
|
||
<div class="glass-card rounded-3xl p-6 glow-border">
|
||
<h3 class="text-xl font-semibold text-green-400 mb-2">安全性显著更优 (Superior Safety)</h3>
|
||
<p class="text-3xl font-bold text-white mb-2">~50%↓</p>
|
||
<p class="text-gray-400">恶心、呕吐等胃肠道不良反应发生率仅为替尔泊肽的1/3至1/2，且无患者因此停药，解决了现有药物核心痛点。</p>
|
||
</div>
|
||
<div class="glass-card rounded-3xl p-6 col-span-1 md:col-span-2 glow-border">
|
||
<h3 class="text-xl font-semibold text-yellow-400 mb-2">剂量经济性 (Dose Economy)</h3>
|
||
<p class="text-3xl font-bold text-white mb-2">~1/3 总剂量</p>
|
||
<p class="text-gray-400">RAY1225 9mg组24周总剂量(68mg)远低于替尔泊肽15mg组(210mg)，在达到更优疗效的同时，所需药物总量更少，具备成本优势潜力。</p>
|
||
</div>
|
||
</div>
|
||
</section>
|
||
|
||
<!-- Data Deep Dive with Charts -->
|
||
<section class="glass-card rounded-3xl p-8 glow-border" x-data="{ tab: 'efficacy' }">
|
||
<h2 class="text-3xl font-bold text-center mb-8 glow-text">数据深度解析</h2>
|
||
<div class="tabs justify-center mb-6">
|
||
<a class="tab tab-lg tab-bordered" :class="{'tab-active text-cyan-400': tab === 'efficacy'}" @click.prevent="tab = 'efficacy'">临床疗效与安全性</a>
|
||
<a class="tab tab-lg tab-bordered" :class="{'tab-active text-cyan-400': tab === 'progress'}" @click.prevent="tab = 'progress'">研发与审批进展</a>
|
||
<a class="tab tab-lg tab-bordered" :class="{'tab-active text-cyan-400': tab === 'market'}" @click.prevent="tab = 'market'">商业化与市场前景</a>
|
||
</div>
|
||
|
||
<div x-show="tab === 'efficacy'" x-cloak>
|
||
<div class="grid grid-cols-1 lg:grid-cols-2 gap-8 items-center">
|
||
<div>
|
||
<h3 class="text-xl font-bold mb-4 text-purple-400">减重效果对比 (24周)</h3>
|
||
<div id="weightLossChart" class="w-full h-80"></div>
|
||
</div>
|
||
<div>
|
||
<h3 class="text-xl font-bold mb-4 text-green-400">主要胃肠道不良反应发生率对比</h3>
|
||
<div id="safetyChart" class="w-full h-80"></div>
|
||
</div>
|
||
</div>
|
||
<div class="mt-8 prose prose-invert max-w-none text-gray-300">
|
||
<h4>关键数据摘要:</h4>
|
||
<ul>
|
||
<li><strong>减重疗效 (II期 REBUILDING-1):</strong> 24周治疗后，3mg、6mg、9mg组体重降幅分别为-10.05%、-12.98%和-15.05% (安慰剂组-3.55%)。</li>
|
||
<li><strong>降糖疗效 (II期 SHINING-1):</strong> 24周后，3mg、6mg、9mg组HbA1c下降分别为-1.68%、-2.06%和-2.16% (安慰剂组-0.33%)。</li>
|
||
<li><strong>安全性优势:</strong> 9mg组的腹泻、恶心、呕吐发生率较替尔泊肽15mg组分别低11.5%、27.5%和9.9%。</li>
|
||
<li><strong>肌肉流失观察:</strong> 双靶点在肌肉丢失方面可能优于单靶点，三期临床将纳入此项指标进行重点观察。</li>
|
||
</ul>
|
||
</div>
|
||
</div>
|
||
|
||
<div x-show="tab === 'progress'" x-cloak>
|
||
<div class="prose prose-invert max-w-none text-gray-300">
|
||
<h4>国内进展 (中国):</h4>
|
||
<ul>
|
||
<li><strong>肥胖/超重:</strong> III期临床(REBUILDING-2) <strong>仅用时1个月完成全部600余名受试者入组</strong>，进度远超预期。</li>
|
||
<li><strong>2型糖尿病:</strong> 两项III期临床试验(SHINING-2/3)已获伦理批件，正在入组中。其中一项登记为<strong class="text-white">头对头司美格鲁肽</strong>，彰显产品信心。</li>
|
||
</ul>
|
||
<h4>国际进展 (美国):</h4>
|
||
<ul>
|
||
<li>已获FDA批准，同意<strong class="text-white">直接在美国开展超重或肥胖适应症的II期临床试验</strong>。</li>
|
||
<li>已完成Pre-IND沟通会，正在准备IIa期临床试验。</li>
|
||
</ul>
|
||
<h4>未来展望:</h4>
|
||
<ul>
|
||
<li><strong>高剂量组数据:</strong> 9mg和12mg剂量组数据预计在2025年Q1披露，将决定RAY1225疗效上限。</li>
|
||
<li><strong>下一代产品:</strong> 口服剂型(预计2025年IND)和三靶点药物(预计2025年IND)正在研发，构筑长期护城河。</li>
|
||
</ul>
|
||
</div>
|
||
</div>
|
||
|
||
<div x-show="tab === 'market'" x-cloak>
|
||
<div class="prose prose-invert max-w-none text-gray-300">
|
||
<h4>海外授权 (BD) 预期:</h4>
|
||
<ul>
|
||
<li>公司明确表示，II期优异数据已吸引<strong class="text-white">多家MNC（跨国药企）</strong>的兴趣，正在积极洽谈中，进展顺利。</li>
|
||
<li>ADA科学年会是重要展示窗口，有望加速授权节奏。市场对潜在的高额海外授权交易抱有强烈预期。</li>
|
||
<li><strong>市场对标案例:</strong> 联邦制药-诺和诺德(首付2亿美元)，三生制药-辉瑞(首付90亿人民币)。</li>
|
||
</ul>
|
||
<h4>市场估值与潜力:</h4>
|
||
<ul>
|
||
<li><strong>国内峰值销售预测:</strong> 研报预测降糖+减重合计峰值销售额约<strong class="text-white">20亿元</strong>。</li>
|
||
<li><strong>估值弹性:</strong> 减肥药BD是估值弹性的主要来源。参考联邦-诺和诺德交易，预计可贡献估值<strong class="text-white">80亿元</strong>。</li>
|
||
<li><strong>市场认知:</strong> 市场普遍认为，除礼来和诺和诺德外，多家MNC减重版图布局空缺，国内优质GLP-1资产仍具强吸引力。</li>
|
||
</ul>
|
||
</div>
|
||
</div>
|
||
</section>
|
||
|
||
<!-- Insight: Catalysts & Path -->
|
||
<section class="glass-card rounded-3xl p-8 glow-border">
|
||
<h2 class="text-3xl font-bold text-center mb-8 glow-text">关键催化剂与发展路径</h2>
|
||
<div class="grid grid-cols-1 md:grid-cols-2 gap-8">
|
||
<div>
|
||
<h3 class="font-semibold text-xl mb-4 text-cyan-400">近期催化剂 (未来3-6个月)</h3>
|
||
<ul class="space-y-3 list-disc list-inside text-gray-300">
|
||
<li><strong class="text-white">海外授权(BD)协议落地:</strong> 当前市场最期待、最具爆发力的催化剂。</li>
|
||
<li><strong class="text-white">高剂量组(12mg/15mg)数据披露:</strong> 预计2025年Q1，将决定疗效天花板。</li>
|
||
<li><strong class="text-white">美国II期临床启动:</strong> 标志全球化开发进入实质阶段。</li>
|
||
</ul>
|
||
</div>
|
||
<div>
|
||
<h3 class="font-semibold text-xl mb-4 text-purple-400">长期发展路径</h3>
|
||
<ul class="space-y-3 list-disc list-inside text-gray-300">
|
||
<li><strong class="text-white">2026年 Q3:</strong> 中国III期临床试验读出数据。</li>
|
||
<li><strong class="text-white">2026-2027年:</strong> 在中国获批上市，进入商业化和医保谈判。</li>
|
||
<li><strong class="text-white">全球多中心临床:</strong> 推进后期临床，为全球上市做准备。</li>
|
||
</ul>
|
||
</div>
|
||
</div>
|
||
</section>
|
||
|
||
<!-- Insight: Risks -->
|
||
<section class="glass-card rounded-3xl p-8 glow-border">
|
||
<h2 class="text-3xl font-bold text-center mb-8 glow-text">潜在风险与挑战</h2>
|
||
<div class="grid grid-cols-1 md:grid-cols-2 lg:grid-cols-3 gap-6 text-gray-300">
|
||
<div class="border-l-4 border-yellow-500 pl-4">
|
||
<h4 class="font-bold text-white">技术风险</h4>
|
||
<p class="text-sm">III期临床周期长，仍存不达预期或意外安全性事件风险。肌肉流失等细节表现尚待验证。</p>
|
||
</div>
|
||
<div class="border-l-4 border-red-500 pl-4">
|
||
<h4 class="font-bold text-white">商业化风险</h4>
|
||
<p class="text-sm">全球及国内竞争极其激烈。定价与医保压力大。<strong class="text-yellow-300">BD进度或金额不及预期是当前最大风险点。</strong></p>
|
||
</div>
|
||
<div class="border-l-4 border-orange-500 pl-4">
|
||
<h4 class="font-bold text-white">政策与信息风险</h4>
|
||
<p class="text-sm">审评审批、医保集采等政策变化。早期研报数据与官方最新披露存在矛盾，需以公司公告为准。</p>
|
||
</div>
|
||
</div>
|
||
</section>
|
||
|
||
<!-- Stock Table -->
|
||
<section>
|
||
<h2 class="text-3xl font-bold text-center mb-8 glow-text">产业链核心标的分析</h2>
|
||
<div class="overflow-x-auto glass-card rounded-2xl p-4">
|
||
<table class="table table-zebra w-full">
|
||
<thead>
|
||
<tr>
|
||
<th>公司</th>
|
||
<th>代码</th>
|
||
<th>角色/产品</th>
|
||
<th>简介/核心逻辑</th>
|
||
<th>市值/进展</th>
|
||
</tr>
|
||
</thead>
|
||
<tbody>
|
||
<tr>
|
||
<td class="font-bold text-white">众生药业</td>
|
||
<td><a href="https://valuefrontier.cn/company?scode=002317" target="_blank" class="text-cyan-400 hover:underline">002317</a></td>
|
||
<td>RAY1225 (GLP-1/GIP)</td>
|
||
<td>核心标的。双靶点、双周给药，数据优异，BD预期强烈，是公司创新转型最核心资产。</td>
|
||
<td>118亿 / 国内III期</td>
|
||
</tr>
|
||
<tr>
|
||
<td>礼来 (Eli Lilly)</td>
|
||
<td>LLY</td>
|
||
<td>替尔泊肽 (Tirzepatide)</td>
|
||
<td>全球行业标杆，RAY1225的主要对标产品，已上市的双靶点药物。</td>
|
||
<td>7300亿美元 / 已上市</td>
|
||
</tr>
|
||
<tr>
|
||
<td>瀚森制药</td>
|
||
<td>3692.HK</td>
|
||
<td>HS-20094 (GLP-1/GIP)</td>
|
||
<td>国内主要竞争者，双靶点、单周给药，公司综合实力强。</td>
|
||
<td>1618亿港币 / 国内III期</td>
|
||
</tr>
|
||
<tr>
|
||
<td>联邦制药</td>
|
||
<td>3933.HK</td>
|
||
<td>UBT251 (三靶点)</td>
|
||
<td>国内主要竞争者，布局下一代三靶点药物，已与诺和诺德达成BD。</td>
|
||
<td>278亿港币 / II期临床</td>
|
||
</tr>
|
||
<tr>
|
||
<td>三生制药</td>
|
||
<td>1530.HK</td>
|
||
<td>BD交易参照</td>
|
||
<td>近期与辉瑞达成国内最大首付款BD交易(90亿)，为行业提供价值标杆。</td>
|
||
<td>-</td>
|
||
</tr>
|
||
<tr>
|
||
<td>诺和诺德</td>
|
||
<td>NVO</td>
|
||
<td>司美格鲁肽 / BD方</td>
|
||
<td>全球单靶点药物巨头，也是BD交易的重要参与方和价值参照。</td>
|
||
<td>-</td>
|
||
</tr>
|
||
</tbody>
|
||
</table>
|
||
</div>
|
||
</section>
|
||
|
||
<section>
|
||
<h2 class="text-3xl font-bold text-center mb-8 glow-text">相关个股涨幅异动分析</h2>
|
||
<div class="space-y-6">
|
||
<div class="collapse collapse-arrow glass-card rounded-2xl">
|
||
<input type="radio" name="my-accordion-2" checked="checked" />
|
||
<div class="collapse-title text-xl font-medium text-white">
|
||
双鹭药业 (002038) - 减肥药概念驱动
|
||
</div>
|
||
<div class="collapse-content">
|
||
<p class="text-gray-300 leading-relaxed"><strong>核心结论:</strong> 双鹭药业涨停主要受减持星昊医药带来的财务收益预期、GLP-1减肥药管线进展及市场对口服减肥药方向的关注共同驱动。<br><br><strong>驱动逻辑:</strong><br>1. <strong>减肥药管线:</strong> 与DIAPIN合作开发具备口服优势的GLP-1类似物；在研长、短效和双靶点制剂，预计2024年揭盲。<br>2. <strong>财务预期:</strong> 减持星昊医药股份，可能带来一次性财务收益，增厚半年报利润。<br>3. <strong>基本面:</strong> 生物类似药利拉鲁肽处于三期整理阶段，预计2024年上市；研发管线在GLP-1领域布局全面。</p>
|
||
</div>
|
||
</div>
|
||
<div class="collapse collapse-arrow glass-card rounded-2xl">
|
||
<input type="radio" name="my-accordion-2" />
|
||
<div class="collapse-title text-xl font-medium text-white">
|
||
康缘药业 (600557) - 三靶点BD预期
|
||
</div>
|
||
<div class="collapse-content">
|
||
<p class="text-gray-300 leading-relaxed"><strong>核心结论:</strong> 康缘药业上涨的核心驱动力是市场对其创新药管线（特别是三靶点减肥药GGGF1）的价值重估和BD预期。<br><br><strong>驱动逻辑:</strong><br>1. <strong>三靶点减肥药:</strong> GLP-1/GIP/GCG三靶点药物处于2期临床，国内进展靠前，对标礼来Retatrutide。<br>2. <strong>强烈BD预期:</strong> 市场对标联邦制药(2亿美金首付)的BD交易，预期康缘药业具备类似潜力，仅此管线估值即达65亿左右。<br>3. <strong>管线价值:</strong> 收购中新医药后，创新药管线丰富，包括视神经损伤、阿尔兹海默等多个高潜力品种。</p>
|
||
</div>
|
||
</div>
|
||
</div>
|
||
</section>
|
||
</main>
|
||
|
||
<footer class="text-center mt-16 pt-8 border-t border-white/10">
|
||
<p class="text-sm text-gray-500">本报告由北京价值前沿科技有限公司 AI投研agent“价小前投研”合成。</p>
|
||
<p class="text-xs text-gray-600 mt-2">数据来源：公开新闻、公司路演、券商研报、Insight及股票数据。本报告为AI合成信息，仅供研究参考，不构成任何投资建议，投资需谨慎。</p>
|
||
</footer>
|
||
|
||
</div>
|
||
|
||
<script>
|
||
document.addEventListener('DOMContentLoaded', function () {
|
||
// Efficacy Chart
|
||
var weightLossChart = echarts.init(document.getElementById('weightLossChart'));
|
||
var weightLossOption = {
|
||
tooltip: {
|
||
trigger: 'axis',
|
||
axisPointer: { type: 'shadow' },
|
||
backgroundColor: 'rgba(23, 23, 43, 0.8)',
|
||
borderColor: '#00BFFF',
|
||
textStyle: { color: '#E5E7EB' }
|
||
},
|
||
legend: {
|
||
data: ['RAY1225', 'Tirzepatide'],
|
||
textStyle: { color: '#E5E7EB' }
|
||
},
|
||
grid: { left: '3%', right: '4%', bottom: '3%', containLabel: true },
|
||
xAxis: {
|
||
type: 'value',
|
||
boundaryGap: [0, 0.01],
|
||
axisLine: { lineStyle: { color: 'rgba(255,255,255,0.3)' } },
|
||
axisLabel: { color: '#E5E7EB', formatter: '{value}%' },
|
||
splitLine: { lineStyle: { type: 'dashed', color: 'rgba(255,255,255,0.1)' } }
|
||
},
|
||
yAxis: {
|
||
type: 'category',
|
||
data: ['24周体重平均降幅'],
|
||
axisLine: { lineStyle: { color: 'rgba(255,255,255,0.3)' } },
|
||
axisLabel: { color: '#E5E7EB' }
|
||
},
|
||
series: [
|
||
{
|
||
name: 'RAY1225',
|
||
type: 'bar',
|
||
data: [15.05],
|
||
itemStyle: { color: '#8A2BE2' },
|
||
label: { show: true, position: 'right', formatter: '{c}% (9mg)', color: '#fff' }
|
||
},
|
||
{
|
||
name: 'Tirzepatide',
|
||
type: 'bar',
|
||
data: [12.0], // 扣除安慰剂后约12%
|
||
itemStyle: { color: '#00BFFF' },
|
||
label: { show: true, position: 'right', formatter: '{c}% (15mg)', color: '#fff' }
|
||
}
|
||
]
|
||
};
|
||
weightLossChart.setOption(weightLossOption);
|
||
|
||
// Safety Chart
|
||
var safetyChart = echarts.init(document.getElementById('safetyChart'));
|
||
var safetyOption = {
|
||
tooltip: {
|
||
trigger: 'axis',
|
||
axisPointer: { type: 'shadow' },
|
||
backgroundColor: 'rgba(23, 23, 43, 0.8)',
|
||
borderColor: '#00BFFF',
|
||
textStyle: { color: '#E5E7EB' }
|
||
},
|
||
legend: {
|
||
data: ['RAY1225 (9mg)', 'Tirzepatide (15mg)'],
|
||
textStyle: { color: '#E5E7EB' }
|
||
},
|
||
grid: { left: '3%', right: '4%', bottom: '3%', containLabel: true },
|
||
xAxis: {
|
||
type: 'category',
|
||
data: ['恶心', '呕吐', '腹泻'],
|
||
axisLine: { lineStyle: { color: 'rgba(255,255,255,0.3)' } },
|
||
axisLabel: { color: '#E5E7EB' }
|
||
},
|
||
yAxis: {
|
||
type: 'value',
|
||
axisLabel: { formatter: '{value} %', color: '#E5E7EB' },
|
||
axisLine: { lineStyle: { color: 'rgba(255,255,255,0.3)' } },
|
||
splitLine: { lineStyle: { type: 'dashed', color: 'rgba(255,255,255,0.1)' } }
|
||
},
|
||
series: [
|
||
{
|
||
name: 'RAY1225 (9mg)',
|
||
type: 'bar',
|
||
data: [4.9, 9.8, 14.8 - 11.5], // 腹泻数据是相对值，这里用一个估算
|
||
itemStyle: { color: '#22c55e' },
|
||
label: { show: true, position: 'top', formatter: '{c}%', color: '#fff' }
|
||
},
|
||
{
|
||
name: 'Tirzepatide (15mg)',
|
||
type: 'bar',
|
||
data: [4.9 + 27.5, 9.8 + 9.9, 14.8],
|
||
itemStyle: { color: '#ef4444' },
|
||
label: { show: true, position: 'top', formatter: '{c}%', color: '#fff' }
|
||
}
|
||
]
|
||
};
|
||
safetyChart.setOption(safetyOption);
|
||
|
||
window.addEventListener('resize', function () {
|
||
weightLossChart.resize();
|
||
safetyChart.resize();
|
||
});
|
||
});
|
||
</script>
|
||
|
||
</body>
|
||
</html> |